# Napigen

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/napigen

- Industry: Biotechnology
- Headquarters: Wilmington, US
- Website: www.napigen.com
- Total disclosed funding: $7.9M
- Latest round: Seed (Jul 12, 2022)
- Investors on record: 6

## About

Based in Delaware, US, and founded in 2016, Napigen operates as a biotechnology company. The company was founded by its CEO Hajime Sakai, Ganesh Kishore, Roger Wyse, and Jay Keasling. In July 2022, Napigen, Inc. raised USD 7.9 million in seed funding co-led by the Grantham Foundation and RA Capital Management, MARSBIO, and the United Mitochondrial Disease Foundation.

Napigen provides genome technology that focuses on changing cytoplasmic genomes, such as mitochondria and chloroplasts, enabling advancements in agribusiness, industrial biotechnology, and medical research. With the use of the company’s hybridization technology, crop plants that are now primarily non-hybrid, like wheat, can produce non-GM hybrid seeds, enabling a reduction in deforestation, which in turn helps to safeguard our environment and climate.

The company plans to use the funds raised in July 2022 to develop hybrid seed technology in wheat and rice through gene editing of plant.

## Funding rounds

- Seed, Jul 12, 2022, $7.9M — RA Capital Management, Thrive, Breakout Ventures, Grantham Foundation, MARSBIO, United Mitochondrial Disease Foundation
- Seed, Apr 30, 2019 — Breakout Ventures

## Investors

- Breakout Ventures (https://capitalatlas.ai/funds/breakout-ventures) — Seed
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Seed
- Thrive (https://capitalatlas.ai/funds/thrive) — Seed
- Grantham Foundation — Seed
- MARSBIO (https://capitalatlas.ai/funds/marsbio) — Seed
- United Mitochondrial Disease Foundation — Seed